Chimeric Bacteriocins for Outer Membrane Transit and Cell Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial treatments are vulnerable to antibiotic-resistant Gram-negative bacteria due to the outer membrane permeability barrier, which prevents externally applied peptides from accessing the peptidoglycan layer, necessitating improved methods to target and degrade this layer for effective bacterial control.
Innovation Solution
Development of chimeric bacteriocin constructs that combine a receptor-mediated translocation domain with a cargo domain, such as a muralytic enzyme, to traverse the outer membrane of Gram-negative bacteria and degrade the peptidoglycan layer, thereby causing cell lysis or disrupting bacterial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic-resistant Gram-negative bacteria survive due to the outer membrane permeability barrier
Solution Approach 1:
The invention creates chimeric bacteriocin constructs that combine a receptor-mediated translocation domain with a cargo domain (such as muralytic enzymes). This composite structure allows the bacteriocin to first bind to outer membrane receptors, translocate across the permeability barrier, and then deliver the cargo domain to the peptidoglycan layer, effectively overcoming the outer membrane barrier that protects antibiotic-resistant bacteria
Solution Approach 2:
The receptor-mediated translocation domain acts as an intermediary that facilitates the delivery of the cargo domain across the outer membrane. The bacteriocin construct uses this intermediary mechanism to transport therapeutic agents or detectable labels from the extracellular space into the periplasmic space, bypassing the permeability barrier that blocks conventional antibiotics
2Reliability
If the outer membrane is targeted to improve bacterial killing, then access to the peptidoglycan layer is blocked, but effective bacterial control requires degradation of this layer
Solution Approach 1:
The bacteriocin construct is segmented into distinct functional domains: a receptor-mediated translocation domain for crossing the outer membrane, and a cargo domain (such as muralytic enzymes) for degrading the peptidoglycan layer. This segmentation allows each domain to perform its specific function sequentially, first overcoming the outer membrane barrier and then accessing and degrading the peptidoglycan layer
Solution Approach 2:
The receptor-mediated translocation domain performs preliminary action by first binding to outer membrane receptors and facilitating translocation across the outer membrane before the cargo domain can access and degrade the peptidoglycan layer. This preliminary translocation step is essential for enabling subsequent peptidoglycan degradation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric bacteriocin constructs effectively target and degrade the peptidoglycan layer of Gram-negative bacteria, enhancing bacterial killing efficiency and providing a mechanism to deliver detectable labels or therapeutic agents inside the cell.
Implementation Method 1
a bacteriocin-derived receptor-mediated translocation domain linked to a cargo domain
Implementation Method 2
contacting the construct with a target Gram-negative bacteria under appropriate conditions, wherein the construct kills the target bacteria
Data Source
Figure 1~2B
Figure 3~4
Figure 5~6
AI summary
The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.